112 results on '"Ravanat C"'
Search Results
2. Removal of citrate from PAS-III additive solution improves functional and biochemical characteristics of buffy-coat platelet concentrates stored for seven days, with or without Intercept pathogen reduction
3. Human platelets labeled at two discrete biotin densities are functional in vitro and are detected in vivo in the mouse circulation. A promising approach to monitor in vivo platelet survival in clinical research
4. Targeting platelet GPIbβ decreases GPIb-dependent signaling, platelet procoagulant activity and arterial thrombosis: PB 2.26–1
5. PRESERVED FUNCTIONAL AND BIOCHEMICAL CHARACTERISTICS OF PLATELET COMPONENTS PREPARED WITH AMOTOSALEN AND UVA FOR PATHOGEN INACTIVATION: 4C-S30–01
6. Further pharmacological and histological characterization of a model of laser-induced localized thrombosis in mesenteric arterioles with standardized moderate and severe injuries: OC-TH-034
7. The initial steps of thrombus formation induced by human atherosclerotic plaques: OC-MO-124
8. Xenograft rejection: molecular mechanisms and therapeutic prospects
9. Synthesis of GPIbβ with novel transmembrane and cytoplasmic sequences in a Bernard–Soulier patient resulting in GPIb-defective signaling in CHO cells
10. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases
11. L’inactivation des pathogènes par la technologie Intercept® préserve l’ultrastructure et les propriétés biochimiques des plaquettes au cours de leur conservation en vue de transfusion
12. Test de génération de thrombine après traitement photochimique et conservation de plasma dérivé de sang total
13. Traitement photochimique d’un mélange de plasmas issus de sang total et congélation dans un délai de 18 à 19heures après le prélèvement
14. Caractéristiques du plasma traité par Intercept™ Blood System pour l’inactivation des agents pathogènes et conservé à 4°C pendant 14jours
15. Proteolysis of the exodomain of recombinant protease-activated receptors (PARs): prediction of receptor activation or inactivation by MALDI-mass spectrometry
16. Use of von Willebrand diseased kidney as donor in a pig-to-primate model of xenotransplantation
17. La morphologie ultrastructurale et les paramètres métaboliques des globules rouges traités par le procédé INTERCEPT-RBC sont préservés au cours du stockage
18. L’inactivation des pathogènes par la technologie Intercept® préserve les propriétés fonctionnelles et biochimiques des plaquettes au cours de leur conservation en vue de transfusion
19. Caractéristiques du plasma traité par Intercept™ Blood System pour l’inactivation des agents pathogènes et conservé à 4 °C pendant 14 jours
20. Traitement photochimique d’un mélange de plasmas issus de sang total et congélation dans un délai de 18 à 19 heures après le prélèvement
21. REDUCED ATHEROSCLEROTIC LESIONS IN P2Y1/APOE DOUBLE KNOCKOUT MICE
22. Human platelets labeled at two discrete biotin densities are functional in vitro and are detected in vivo in the mouse circulation. A promising approach to monitor in vivo platelet survival in clinical research.
23. One-step assay for the determination of free protein S antigen in plasma using real-time biospecific interaction analysis
24. Species Specific Immunoassays to Measure Blood Platelet and Coagulation Activation in the Rat
25. Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species
26. Use of annexin-V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells
27. The catalytic role of anionic phospholipids in the activation of protein C by factor Xa and expression of its anticoagulant function in human plasma
28. Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist.
29. Xenograft rejection: molecular mechanisms and therapeutic prospects.
30. Diets enriched in (n-3) fatty acids affect rat coagulation factors dependent on vitamin K
31. PF4 inhibits thrombin-stimulated MMP-1 and MMP-3 metalloproteinase expression in human vascular endothelial cells
32. The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa
33. A platelet aggregation defect in response to all agonists in a patient with mild thrombocytopenia and a shortened platelet lifespan: A critical role for PDE3
34. A novel monoclonal antibody against the extracellular domain of GPIbbeta modulates vWF mediated platelet adhesion
35. Adsorption/desorption of a PEO-rich comb-like polymer at a silica/aqueous solution interface
36. A neutron solution scattering study of the structure of annexin-V and its binding to lipid vesicle
37. Proteolysis of the Exodomain of Recombinant Protease-Activated Receptors: Prediction of Receptor Activation or Inactivation by MALDI Mass Spectrometry
38. L’inactivation des pathogènes par la technologie Intercept® préserve les propriétés fonctionnelles et biochimiques des plaquettes au cours de leur conservation en vue de transfusion
39. Glycoprotein V : the unsolved GPV puzzle.
40. Human platelets labeled at two discrete biotin densities are functional in vitro and are detected in vivo in the murine circulation: A promising approach to monitor platelet survival in vivo in clinical research.
41. Removal of citrate from PAS-III additive solution improves functional and biochemical characteristics of buffy-coat platelet concentrates stored for 7 days, with or without INTERCEPT pathogen reduction.
42. In vitro quality of amotosalen-UVA pathogen-inactivated mini-pool plasma prepared from whole blood stored overnight.
43. Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance.
44. Delayed-onset of procoagulant signalling revealed by kinetic analysis of COAT platelet formation.
45. Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivation.
46. Dehydration of blood platelets by zeodration: in vitro characterization and hemostatic properties in vivo.
47. Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis.
48. The P2X1 receptor is required for neutrophil extravasation during lipopolysaccharide-induced lethal endotoxemia in mice.
49. Targeting platelet GPIbβ reduces platelet adhesion, GPIb signaling and thrombin generation and prevents arterial thrombosis.
50. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.